This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT00492895
First received: June 19, 2007
Last updated: January 28, 2013
Last verified: January 2013
  Purpose
Photosensitivity of the skin to UVA and UVB will be determined

Condition Intervention Phase
Skin Cancer Drug: Discontinuation of Azathioprin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Photosensitivity of the skin to UVA and UVB [ Time Frame: 2 years ]

Enrollment: 25
Study Start Date: June 2007
Study Completion Date: March 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A
one arm only. Crossover study
Drug: Discontinuation of Azathioprin
Discontinuation of Azathioprin

Detailed Description:

Photosensitivity of the skin to UVA and UVB in renal transplant recipients with and without azathioprine will be determined. Azathioprine will be discontinued and photosensitivity determined after a wash-out period of three months

  • Trial with medicinal product
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Renal transplant recipients under azathioprin

Exclusion criteria:

  • Treatment with Prograf (Tacrolimus)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00492895

Locations
Switzerland
Clinic for Dermatology, University Hospital of Zurich
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Günther Hofbauer, M.D UniversitaetsSpital Zuerich
  More Information

Publications:
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT00492895     History of Changes
Other Study ID Numbers: 2007DR2040
Study First Received: June 19, 2007
Last Updated: January 28, 2013

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms by Site
Neoplasms
Skin Diseases

ClinicalTrials.gov processed this record on June 27, 2017